Form 8-K CYTOKINETICS INC For: Jul 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Cytokinetics (CYTK) Valuation Remains Attractive Following Q2 Results - Roth
July 31, 2014 2:17 PM EDTRoth Capital reaffirms its Buy rating and $13 price target on Cytokinetics (Nasdaq: CYTK) following the company's Q2 report.
Ahead of the bell, Cytokinetics posted Q2 loss of $0.23 per share with revenue of $7.8 million, versus consensus estimates calling for a loss of $0.32 per share and revs of $7.0 million. Roth was looking for a loss of $0.38 per share and revenue of $4.0 million.
Roth analyst Joseph Pantginis... More
